We are analyzing https://link.springer.com/article/10.1007/s12032-025-02735-z.

Title:
CAR T-cell therapy in renal cell carcinoma: opportunities, challenges, and new strategies to overcome | Medical Oncology
Description:
Immunotherapy is a biological treatment for cancer that utilizes substances sourced from live organisms. Immunotherapy encompasses several modalities, including monoclonal antibodies, therapeutic vaccinations, immune system modulators, T-cell transfer treatment, and immune checkpoint inhibitors (ICIs). It may treat kidney cancer by modifying the immune system
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

pubmed, article, google, scholar, cell, cas, central, therapy, renal, cancer, car, carcinoma, cart, cells, tcell, immunotherapy, treatment, antigen, chimeric, tumor, wang, receptor, oncol, strategies, immune, kidney, mohammadi, current, mol, research, review, najafi, study, sci, medical, checkpoint, cytokine, access, front, cancers, clin, res, med, overcoming, kermanshah, privacy, cookies, content, data, challenges,

Topics {✒️}

car-t-derived extracellular vesicles life-threatening car t-cell antigen-specific t-cell immunotherapy month download article/chapter advanced renal-cell carcinoma large b-cell lymphoma interferon-alpha administered intermittently car t-cell therapy car t-cell killing ph-low insertion peptide chimeric antigen-based approach chimeric antigen receptor-engineered t-cell transfer treatment renal cell carcinoma cart cell therapy cytokine release syndrome t-cell therapy cell-free therapeutic strategies full article pdf cell death discovery renal cell tumors chimeric antigen receptor related subjects chávez-escamilla ak pantea mohammadi contributed nk cell therapy tacheva-grigorova sk adoptive cell therapies privacy choices/manage cookies t-cell exhaustion t-cell treatment b-cell malignancies acute kidney injury nat rev urol anti-tumor therapy chimeric antigen receptors trans cell ther controlling cell trafficking cell tiss bank houshang najafi caix-specific car emerging cancer immunotherapy immune checkpoint inhibitors bmj specialist journals article mohammadi car-nk cell peptide-loading complex treat kidney cancer cells targeting cd70 blood vessel injury

Schema {🗺️}

WebPage:
      mainEntity:
         headline:CAR T-cell therapy in renal cell carcinoma: opportunities, challenges, and new strategies to overcome
         description:Immunotherapy is a biological treatment for cancer that utilizes substances sourced from live organisms. Immunotherapy encompasses several modalities, including monoclonal antibodies, therapeutic vaccinations, immune system modulators, T-cell transfer treatment, and immune checkpoint inhibitors (ICIs). It may treat kidney cancer by modifying the immune system's reaction to cancerous cells. These medicines are delivered as ICIs or cytokines. Immunotherapy may sometimes be used with targeted therapies, such as CAR T-cell therapy, to improve outcomes in advanced cancer. Chimeric Antigen Receptor (CAR) T-cell therapy is a kind of cancer immunotherapy using genetically engineered T cells to augment their capacity to eradicate cancer cells. Although CAR T-cell therapy has achieved success, it continues to have substantial limitations that necessitate further investigation. Antigen escape, inhibition and resistance in B-cell malignancies, and life-threatening CAR T-cell-associated toxicities, such as cytokine release syndrome, neurologic toxicities, and sustained cytopenias, are among their limitations. Renal cell carcinoma RCC is the most common type of kidney cancer in adults. The surgical excision of a portion or the entire kidney is a common treatment for RCC. This procedure has the potential to cause agony, as well as organ and blood vessel injury. This study has examined the benefits of T cell therapy in the treatment of RCC, as well as the challenges and issues associated with this treatment method. It has also examined effective strategies for reducing the side effects, in light of the importance and incidence rate of this type of cancer.
         datePublished:2025-04-24T00:00:00Z
         dateModified:2025-04-24T00:00:00Z
         pageStart:1
         pageEnd:14
         sameAs:https://doi.org/10.1007/s12032-025-02735-z
         keywords:
            Immunotherapy
            Chimeric Antigen Receptor T cell
            Renal cell carcinoma
            Cytokine release syndrome
            Exosome
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02735-z/MediaObjects/12032_2025_2735_Figa_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02735-z/MediaObjects/12032_2025_2735_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02735-z/MediaObjects/12032_2025_2735_Fig2_HTML.png
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
            volumeNumber:42
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Mahan Mohammadi
               affiliation:
                     name:Kermanshah University of Medical Sciences
                     address:
                        name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Houshang Najafi
               affiliation:
                     name:Kermanshah University of Medical Sciences
                     address:
                        name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
                        type:PostalAddress
                     type:Organization
                     name:Kermanshah University of Medical Sciences
                     address:
                        name:Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Pantea Mohammadi
               affiliation:
                     name:Kermanshah University of Medical Sciences
                     address:
                        name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:CAR T-cell therapy in renal cell carcinoma: opportunities, challenges, and new strategies to overcome
      description:Immunotherapy is a biological treatment for cancer that utilizes substances sourced from live organisms. Immunotherapy encompasses several modalities, including monoclonal antibodies, therapeutic vaccinations, immune system modulators, T-cell transfer treatment, and immune checkpoint inhibitors (ICIs). It may treat kidney cancer by modifying the immune system's reaction to cancerous cells. These medicines are delivered as ICIs or cytokines. Immunotherapy may sometimes be used with targeted therapies, such as CAR T-cell therapy, to improve outcomes in advanced cancer. Chimeric Antigen Receptor (CAR) T-cell therapy is a kind of cancer immunotherapy using genetically engineered T cells to augment their capacity to eradicate cancer cells. Although CAR T-cell therapy has achieved success, it continues to have substantial limitations that necessitate further investigation. Antigen escape, inhibition and resistance in B-cell malignancies, and life-threatening CAR T-cell-associated toxicities, such as cytokine release syndrome, neurologic toxicities, and sustained cytopenias, are among their limitations. Renal cell carcinoma RCC is the most common type of kidney cancer in adults. The surgical excision of a portion or the entire kidney is a common treatment for RCC. This procedure has the potential to cause agony, as well as organ and blood vessel injury. This study has examined the benefits of T cell therapy in the treatment of RCC, as well as the challenges and issues associated with this treatment method. It has also examined effective strategies for reducing the side effects, in light of the importance and incidence rate of this type of cancer.
      datePublished:2025-04-24T00:00:00Z
      dateModified:2025-04-24T00:00:00Z
      pageStart:1
      pageEnd:14
      sameAs:https://doi.org/10.1007/s12032-025-02735-z
      keywords:
         Immunotherapy
         Chimeric Antigen Receptor T cell
         Renal cell carcinoma
         Cytokine release syndrome
         Exosome
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02735-z/MediaObjects/12032_2025_2735_Figa_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02735-z/MediaObjects/12032_2025_2735_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02735-z/MediaObjects/12032_2025_2735_Fig2_HTML.png
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
         volumeNumber:42
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Mahan Mohammadi
            affiliation:
                  name:Kermanshah University of Medical Sciences
                  address:
                     name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Houshang Najafi
            affiliation:
                  name:Kermanshah University of Medical Sciences
                  address:
                     name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
                     type:PostalAddress
                  type:Organization
                  name:Kermanshah University of Medical Sciences
                  address:
                     name:Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Pantea Mohammadi
            affiliation:
                  name:Kermanshah University of Medical Sciences
                  address:
                     name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
      volumeNumber:42
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Kermanshah University of Medical Sciences
      address:
         name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
         type:PostalAddress
      name:Kermanshah University of Medical Sciences
      address:
         name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
         type:PostalAddress
      name:Kermanshah University of Medical Sciences
      address:
         name:Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
         type:PostalAddress
      name:Kermanshah University of Medical Sciences
      address:
         name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Mahan Mohammadi
      affiliation:
            name:Kermanshah University of Medical Sciences
            address:
               name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
               type:PostalAddress
            type:Organization
      name:Houshang Najafi
      affiliation:
            name:Kermanshah University of Medical Sciences
            address:
               name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
               type:PostalAddress
            type:Organization
            name:Kermanshah University of Medical Sciences
            address:
               name:Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Pantea Mohammadi
      affiliation:
            name:Kermanshah University of Medical Sciences
            address:
               name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
      name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
      name:Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
      name:Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(243)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.92s.

LINK . SPRINGER . COM {}